Drug Trial Radar · NCT04432584
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
190
Planned (sponsor's estimate)
Start
Sep 30, 2020
Primary completion
Apr 18, 2027
Study completion Apr 18, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Jun 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 190 participants.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
CrovalimabDrug
Dosing depends on body weight. Participants will be dosed as follows: * 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study * 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study * 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study * 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study * 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study * 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study.
EculizumabDrug
Eculizumab will be administered at a dose of 900 mg Q2W, as per the dosing schedule described above.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events (AEs) and by SeverityTime frame: Up to approximately 6 years
- Percentage of Participants With Injection-site Reactions, Infusion-related Reactions, Hypersensitivity and Infections (including Meningococcal Meningitis)Time frame: Up to approximately 6 years
- Percentage of Participants With Adverse Events (AEs) Leading to Study Drug DiscontinuationTime frame: Up to approximately 6 years
- Percentage of Participants With Clinical Manifestations of Drug-target-drug Complex (DTDC) Formation Amongst Those Participants Who Switched to Crovalimab Treatment From Eculizumab Treatment or Ravulizumab TreatmentTime frame: Up to approximately 6 years
Locations
80 sites in 24 countries. Site status is shown where the registry gives one.
Carolinas Healthcare System
Charlotte, North Carolina
Nationwide Children's Hospital
Columbus, Ohio
Cliniques Universitaires Saint-Luc
Brussels, Belgium
AZ Delta Campus Westlaan
Roeselare, Belgium
Beneficencia Portuguesa de Sao Paulo
São Paulo, Brazil
Chronos Pesquisa Clinica
Taguatinga, Federal District, Brazil
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas de Porto Alegre X
Porto Alegre, Rio Grande do Sul, Brazil
Instituto Joinvilense de Hematologia E Oncologia
Joinville, Santa Catarina, Brazil
Hospital das Clínicas FMRP-USP
Ribeirão Preto, São Paulo, Brazil
*X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
Santo André, São Paulo, Brazil
Hospital Sírio-Libanês
São Paulo, São Paulo, Brazil
Hospital Paulistano
São Paulo, São Paulo, Brazil
Ustav hematologie a krevni transfuze
Prague, Czechia
North Estonia Medical Centre Foundation
Tallinn, Estonia
Hopital Claude Huriez - CHU Lille
Lille, France
Institut Paoli Calmette
Marseille, France
Universitaetsklinikum Aachen AOeR
Aachen, Germany
ELBLANDKLINIKUM Riesa
Riesa, Germany
General Hospital of Athens LAIKO
Athens, Greece
Attikon University General Hospital
Athens, Greece
Prince of Wales Hospital
Hong Kong, Hong Kong
Semmelweis Egyetem
Budapest, Hungary
St James's Hospital
Dublin, Ireland
Azienda Unita Sanitaria Locale- Ravenna
Ravenna, Emilia-Romagna, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Lazio, Italy
Fondazione IRCCS CA? Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Turin, Piedmont, Italy
Azienda Ospedaliera Universitaria Careggi
Florence, Tuscany, Italy
Fujita Health University Hospital
Aichi, Japan
Kobe University Hospital
Hyōgo, Japan
Tokushukai Takasago Seibu Hospital
Hyōgo, Japan
Ishikawa Prefectural Central Hospital
Ishikawa, Japan
Tokai University Hospital
Kanagawa, Japan
Mie University Hospital
Mie, Japan
Japanese Red Cross Society Suwa Hospital
Nagano, Japan
Nagasaki University Hospital
Nagasaki, Japan
Sasebo City General Hospital
Nagasaki, Japan
National Hospital Organization Okayama Medical Center
Okayama, Japan
The University of Osaka Hospital
Osaka, Japan
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.